Search

In the present study the white-rot fungi BP was selected to study the degradation of nitrogen heterocyclic compounds in real and simulated coking wastewater. The study incorporated analysis of the degradation process, mechanism of action of white-rot fungi on nitrogen heterocyclic compounds, changes of enzyme activity and white-rot fungi biomass growth rate in coking wastewater (simulated and actual). The results showed that addition of ammonia nitrogen and phenol in simulated wastewater had insignificant effects on the degradation of indole. Moreover, the promoting effect of phenol on quinoline degradation was greater than the inhibition effects of ammonia nitrogen. Degradation rates of quinoline, indole and pyridine are consistent with the zero-order kinetics equation. It was also found that the addition of Mg (II) and Mn (II) promotes the degradation of quinoline by white-rot fungi in the actual wastewater, while degradation of pyridine was inhibited by three ions, out of which the inhibition of Cu (II) was the most obvious. Cu (II) was also found to have positive effects on the levels of activity of laccase enzyme secreted by the white-rot fungi as opposed to other metal ions tested. However, it was found to have inhibitory effects on the development of white-rot fungi, while Mg (II) and Mn (II) were found to promote the development of the white-rot fungi. The activity of the enzyme and the growth rate of biomass of white-rot fungi first reached the maximum levels followed by a significant decline.

Background: Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge., Methods: Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis., Results: Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P=0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P<0.001) and critical illness (4.4% vs. 0.5%, P=0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P<0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P=0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia., Conclusions: 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS., (Copyright © 2021 Elsevier España, S.L.U. All rights reserved.)